WaveMan
WaveMan · Company
COYA · Coya Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

COYA Coya Therapeutics (COYA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001835022
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
21
13F, latest reported quarter

Coya Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Coya Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
SNYDER DAVID S
Chief Financial Officer
BUY
2024-11-14 SEC
1,800
$12.9K
-37.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 20.5% of the 8,800 shares held after it.
  • 2 other insiders bought within 30 days.
  • 21 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer SNYDER DAVID S bought about $12.9K of COYA on Nov 14, 2024; 2 other insiders bought within 30 days and 21 funds added in the latest 13F quarter.
Swaminathan Arun
Chief Executive Officer
BUY
2024-11-13 SEC
5,000
$36.8K
-42.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 11, 2024.
  • The trade is 50.0% of the 10,000 shares held after it.
  • 2 other insiders bought within 30 days.
  • 21 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Swaminathan Arun bought about $36.8K of COYA on Nov 13, 2024, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 21 funds added in the latest 13F quarter.
Grossman Fred
Chief Medical Officer
BUY
2024-11-12 SECtraded 2024-11-11
2,710
$20.0K
-45.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 2,710 shares held after it.
  • 2 other insiders bought within 30 days.
  • 21 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Grossman Fred bought about $20.0K of COYA on Nov 11, 2024, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 21 funds added in the latest 13F quarter.
Swaminathan Arun
Chief Executive Officer
BUY
2024-11-12 SECtraded 2024-11-11
5,000
$36.7K
-45.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 5,000 shares held after it.
  • 2 other insiders bought within 30 days.
  • 21 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Swaminathan Arun bought about $36.7K of COYA on Nov 11, 2024, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 21 funds added in the latest 13F quarter.
Lee Ann
Director
BUY
2024-03-05 SECtraded 2023-08-22
1,000
$3.6K
-59.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 5.7% of the 17,479 shares held after it.
  • No other insider bought within 30 days.
  • 21 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Lee Ann bought about $3.6K of COYA on Aug 22, 2023, the largest insider purchase at the company on our record; 21 funds added in the latest 13F quarter.
12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 7 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
21 funds bought in last quarter
below 67% of Pharma & Biotech
Revenue
+123.6% year over year
more than 86% of Pharma & Biotech
Margin
-267.1% net margin
below 70% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.2% of the float short (float per yahoo 2026-10-27) · 8.6 days to cover · settled 2026-10-15
more than 53% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch COYA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-43.4%12M
-46%-31%-15%+0%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns COYA: institutional holders (13F)

13F holdings, latest reported quarter
DME Capital Management, LP
2,335,540 sh
$13.7M
VANGUARD CAPITAL MANAGEMENT LLC
842,220 sh
$4.9M
Alyeska Investment Group, L.P.
800,000 sh
$4.7M
AIGH Capital Management LLC
631,912 sh
$3.7M
CM Management, LLC
400,000 sh
$2.3M

Congress trades in COYA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

COYA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

COYA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$385.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$25.9K position · as of 2026-06-30
0.0%
Dimensional US Vector Equity ETF
$20.1K position · as of 2026-07-31
0.0%
Dimensional U.S. Small Cap ETF
$316.6K position · as of 2026-07-31
0.0%
U.S. MICRO CAP PORTFOLIO
$155.7K position · as of 2026-07-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$1.3M position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Multi-phase
1 active
What changed recently
Study of COYA 302 for the Treatment of ALS
2026-10-14 · Completion moved 2027-01 → 2027-04
PHASE2,PHASE3
Study of COYA 302 for the Treatment of ALS
2026-10-14 · Recruiting → Active Not Recruiting
PHASE2,PHASE3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 21 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

COYA financials

Revenue growth
+123.6%
XBRL, annual
Net margin
-267.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$8.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-270.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-60.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-53.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-63.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$7.9M$3.6M$6.0M$0
Operating income-$22.6M-$17.2M-$7.9M-$9.8M
Net income-$21.2M-$14.9M-$8.0M-$12.2M
EPS (diluted)-1.27-0.98-0.79-4.73
Operating cash flow-$10.7M-$10.3M-$11.2M-$7.2M
Cash$46.8M$38.3M$32.6M$5.9M
SEC XBRL, fiscal years, as known on 2026-10-28

COYA Stock Sonar score 4/7 axes

Find similar shapesCompare

COYA ranks highest on growth (86th percentile) and risk and compliance (74th), and lowest on institutional and government (33rd), among Pharma & Biotech peers.

Profitability
43
Inputs
  • Return on equity-60.5% · 48 pct, sector of 545
  • Return on assets-53.7% · 42 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-63.6% · 39 pct, sector of 576
Growth
86
Inputs
  • Revenue growth, YoY+123.6% · 86 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
33
Inputs
  • Funds adding, latest quarter21 · 33 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
74
Inputs
  • Short interest, % of float+7.2% · 49 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+1.1% · 98 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies